1. Pulmonary cancers across different histotypes share hybrid tuft cell/ionocyte-like molecular features and potentially druggable vulnerabilities
- Author
-
40742622, 10252462, 60252962, Yamada, Yosuke, Belharazem-Vitacolonnna, Djeda, Bohnenberger, Hanibal, Weiß, Christel, Matsui, Naoko, Kriegsmann, Mark, Kriegsmann, Katharina, Sinn, Peter, Simon-Keller, Katja, Hamilton, Gerhard, Graeter, Thomas, Preissler, Gerhard, Ott, German, Schölch, Sebastian, Nakajima, Naoki, Yoshizawa, Akihiko, Haga, Hironori, Date, Hiroshi, Thomas, Roman K., Petrini, Iacopo, Giaccone, Giuseppe, Ströbel, Philipp, Marx, Alexander, 40742622, 10252462, 60252962, Yamada, Yosuke, Belharazem-Vitacolonnna, Djeda, Bohnenberger, Hanibal, Weiß, Christel, Matsui, Naoko, Kriegsmann, Mark, Kriegsmann, Katharina, Sinn, Peter, Simon-Keller, Katja, Hamilton, Gerhard, Graeter, Thomas, Preissler, Gerhard, Ott, German, Schölch, Sebastian, Nakajima, Naoki, Yoshizawa, Akihiko, Haga, Hironori, Date, Hiroshi, Thomas, Roman K., Petrini, Iacopo, Giaccone, Giuseppe, Ströbel, Philipp, and Marx, Alexander
- Abstract
Tuft cells are chemosensory epithelial cells in the respiratory tract and several other organs. Recent studies revealed tuft cell-like gene expression signatures in some pulmonary adenocarcinomas, squamous cell carcinomas (SQCC), small cell carcinomas (SCLC), and large cell neuroendocrine carcinomas (LCNEC). Identification of their similarities could inform shared druggable vulnerabilities. Clinicopathological features of tuft cell-like (tcl) subsets in various lung cancer histotypes were studied in two independent tumor cohorts using immunohistochemistry (n = 674 and 70). Findings were confirmed, and additional characteristics were explored using public datasets (RNA seq and immunohistochemical data) (n = 555). Drug susceptibilities of tuft cell-like SCLC cell lines were also investigated. By immunohistochemistry, 10–20% of SCLC and LCNEC, and approximately 2% of SQCC expressed POU2F3, the master regulator of tuft cells. These tuft cell-like tumors exhibited “lineage ambiguity” as they co-expressed NCAM1, a marker for neuroendocrine differentiation, and KRT5, a marker for squamous differentiation. In addition, tuft cell-like tumors co-expressed BCL2 and KIT, and tuft cell-like SCLC and LCNEC, but not SQCC, also highly expressed MYC. Data from public datasets confirmed these features and revealed that tuft cell-like SCLC and LCNEC co-clustered on hierarchical clustering. Furthermore, only tuft cell-like subsets among pulmonary cancers significantly expressed FOXI1, the master regulator of ionocytes, suggesting their bidirectional but immature differentiation status. Clinically, tuft cell-like SCLC and LCNEC had a similar prognosis. Experimentally, tuft cell-like SCLC cell lines were susceptible to PARP and BCL2 co-inhibition, indicating synergistic effects. Taken together, pulmonary tuft cell-like cancers maintain histotype-related clinicopathologic characteristics despite overlapping unique molecular features. From a therapeutic perspective, identification of tuft
- Published
- 2022